Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule

NCT06298409 is registered in ClinicalTrials.gov with Envivo Bio Inc as lead sponsor.

NCT NCT06298409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06298409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule
Lead sponsor
Envivo Bio Inc
Phase
Phase 1
Overall status
Recruiting
Start date
February 15, 2024
Completion date
February 28, 2026
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small intestinal bacterial overgrowth